Management of peripheral arterial disease in the elderly: focus on cilostazol

Travis M Falconer1, John W Eikelboom2, Graeme J Hankey3, Paul E Norman11School of Surgery, University of Western Australia, Fremantle Hospital, Western Australia; 2Department of Medicine, McMaster University, Hamilton, Canada; 3Department of Neurology, Royal Perth Hospital, School of Medicine and Ph...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Travis M Falconer, John W Eikelboom, Graeme J Hankey, Paul E Norman
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/6a2d9c7214b04d26a3b8a15606ef001a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a2d9c7214b04d26a3b8a15606ef001a
record_format	dspace
spelling	oai:doaj.org-article:6a2d9c7214b04d26a3b8a15606ef001a2021-12-02T06:23:58ZManagement of peripheral arterial disease in the elderly: focus on cilostazol1178-1998https://doaj.org/article/6a2d9c7214b04d26a3b8a15606ef001a2008-03-01T00:00:00Zhttps://www.dovepress.com/management-of-peripheral-arterial-disease-in-the-elderly-focus-on-cilo-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Travis M Falconer1, John W Eikelboom2, Graeme J Hankey3, Paul E Norman11School of Surgery, University of Western Australia, Fremantle Hospital, Western Australia; 2Department of Medicine, McMaster University, Hamilton, Canada; 3Department of Neurology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western AustraliaAbstract: Symptomatic and asymptomatic peripheral arterial disease (PAD) is a common problem in the elderly. The management of PAD includes the prevention of cardiovascular events and relief of symptoms – most commonly intermittent claudication (IC). Both require treatment of the causes and consequences of atherothrombosis, but some strategies are more effective for prevention of cardiovascular events and others are more effective for the relief of symptoms. Priorities for the prevention of cardiovascular events include smoking cessation, exercise, antiplatelet therapy, and the treatment of dyslipidemia, hypertension, and diabetes. Walking time and ability are improved by exercise. The benefit of numerous drugs in the treatment of IC has been assessed. The results have generally been disappointing, but there is some evidence that statins and cilostazol (an inhibitor of phosphodiesterase 3) are of benefit. Meta-analyses suggest that cilostazol increases maximum walking distance by 40%–50% and improves other objective measures of walking. The safety profile of cilostazol in patients with PAD appears to be acceptable although the mechanism for its effect on IC is unclear. In addition to risk factor management, treatment with cilostazol should be considered in patients with disabling IC.Keywords: peripheral arterial disease, intermittent claudication, risk factors, cilostazolTravis M FalconerJohn W EikelboomGraeme J HankeyPaul E NormanDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 17-23 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Travis M Falconer John W Eikelboom Graeme J Hankey Paul E Norman Management of peripheral arterial disease in the elderly: focus on cilostazol
description	Travis M Falconer1, John W Eikelboom2, Graeme J Hankey3, Paul E Norman11School of Surgery, University of Western Australia, Fremantle Hospital, Western Australia; 2Department of Medicine, McMaster University, Hamilton, Canada; 3Department of Neurology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western AustraliaAbstract: Symptomatic and asymptomatic peripheral arterial disease (PAD) is a common problem in the elderly. The management of PAD includes the prevention of cardiovascular events and relief of symptoms – most commonly intermittent claudication (IC). Both require treatment of the causes and consequences of atherothrombosis, but some strategies are more effective for prevention of cardiovascular events and others are more effective for the relief of symptoms. Priorities for the prevention of cardiovascular events include smoking cessation, exercise, antiplatelet therapy, and the treatment of dyslipidemia, hypertension, and diabetes. Walking time and ability are improved by exercise. The benefit of numerous drugs in the treatment of IC has been assessed. The results have generally been disappointing, but there is some evidence that statins and cilostazol (an inhibitor of phosphodiesterase 3) are of benefit. Meta-analyses suggest that cilostazol increases maximum walking distance by 40%–50% and improves other objective measures of walking. The safety profile of cilostazol in patients with PAD appears to be acceptable although the mechanism for its effect on IC is unclear. In addition to risk factor management, treatment with cilostazol should be considered in patients with disabling IC.Keywords: peripheral arterial disease, intermittent claudication, risk factors, cilostazol
format	article
author	Travis M Falconer John W Eikelboom Graeme J Hankey Paul E Norman
author_facet	Travis M Falconer John W Eikelboom Graeme J Hankey Paul E Norman
author_sort	Travis M Falconer
title	Management of peripheral arterial disease in the elderly: focus on cilostazol
title_short	Management of peripheral arterial disease in the elderly: focus on cilostazol
title_full	Management of peripheral arterial disease in the elderly: focus on cilostazol
title_fullStr	Management of peripheral arterial disease in the elderly: focus on cilostazol
title_full_unstemmed	Management of peripheral arterial disease in the elderly: focus on cilostazol
title_sort	management of peripheral arterial disease in the elderly: focus on cilostazol
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/6a2d9c7214b04d26a3b8a15606ef001a
work_keys_str_mv	AT travismfalconer managementofperipheralarterialdiseaseintheelderlyfocusoncilostazol AT johnweikelboom managementofperipheralarterialdiseaseintheelderlyfocusoncilostazol AT graemejhankey managementofperipheralarterialdiseaseintheelderlyfocusoncilostazol AT paulenorman managementofperipheralarterialdiseaseintheelderlyfocusoncilostazol
_version_	1718399937764392960

Management of peripheral arterial disease in the elderly: focus on cilostazol

Ejemplares similares